Home>Topics>Companies>Sanofi S.A.

Sanofi S.A.

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. Amgen first to win EU backing for new kind of cholesterol drug

    Headlines

    Fri, 22 May 2015

    May 22 (Reuters) - Amgen Inc's closely watched new cholesterol drug, Repatha, has been recommended for approval in Europe, putting the U.S. drugmaker ahead in a race with rival Sanofi SA .

  2. Funds That Buy Like Buffett 2015

    Headlines

    Thu, 30 Apr 2015

    Moody's MCO "> MCO . The last two are the only newcomers to the top 10, replacing Exxon Mobil XOM "> XOM and Sanofi SNY "> SNY from last year's letter. Plenty of mutual fund managers are Buffett fans who emulate his investment approach in

  3. Sanofi says U.S. FDA to fast track Fabry therapy review

    Headlines

    Tue, 28 Apr 2015

    PARIS, April 28 (Reuters) - French drugmaker Sanofi said on Tuesday that the U.S. Food and Drug Administration has agreed to speed up the review of its drug application for a new Fabry disease treatment.

  4. BRIEF-Innate Pharma and Sanofi collaborate on antibody-drug conjugates

    Headlines

    Thu, 16 Apr 2015

    * Innate Pharma and Sanofi SA collaborate on next generation antibody-drug conjugates

  5. The Ultimate Stock-Pickers’ Top 10 Dividend Stocks

    Headlines

    Tue, 17 Mar 2015

    Medium 8 4 Unilever UL* 2 Wide 42.06 1.11 3.5 Medium 9 4 McDonald's MCD 3 Wide 96.35 0.98 3.4 Medium 5 1 Sanofi SNY * 4 Wide 47.07 0.86 3.4 Medium 6 2 EmersonElec EMR 4 Wide 55.26 0.8 3.3 Medium 7 1 ExxonMobil XOM 4 Wide 83

  6. Sanofi's Appointment of Brandicourt Replaces a Key Uncertainty With a Strong Leader

    Commentary

    Thu, 19 Feb 2015

    Sanofi announced the appointment ..... s ousting of previous CEO Chris Viehbacher in late 2014. While the appointment ..... industry experience should guide Sanofi well through several new product ..... products will be needed as Sanofi prepares to launch several

  7. Our 2014 Big Pharma Pipeline Rankings: Who Came Out on Top?

    Video Reports

    Fri, 2 Jan 2015

    year's ranking, the top two firms were [TICKER: SNY ] Sanofi ( SNY ) and Merck (MRK). And just taking those one at ..... incident rate cancers like lung cancer. [TICKER: SNY ] Sanofi is a firm where the pipeline is not as strong as Merck

    SNY Sanofi found at 1:30, 2:12, 3:51

    ranking and why? Conover: In this year's ranking, the top two firms were [TICKER: SNY ] Sanofi SNY and Merck (MRK). And just taking those one at a time: Merck's a firm that is really in this transitionary period of
    shift in how we treat very large incident rate cancers like lung cancer. [TICKER: SNY ] Sanofi is a firm where the pipeline is not as strong as Merck, but it's a firm that doesn't have a lot of
    having me. Coffina: In conclusion, in this year's Big Pharma ranking, Merck and [TICKER: SNY ] Sanofi came out on top--Merck because of its very strong pipeline and [TICKER: SNY ] Sanofi mostly because of its lack of patent losses over the next five years. On the other end of the spectrum, Pfizer and [TICKER:GSK]
  8. 5 Wide-Moat Stocks That Were Left Behind in 2014

    Video Reports

    Fri, 2 Jan 2015

    care stock did well, including wide-moat [TICKER: SNY ] Sanofi . Glaser: Health-care stocks looked very strong in 2014, driven partially by an M&A boom. But [TICKER: SNY ] Sanofi looked a lot weaker, and there are a few things happening

    SNY Sanofi found at 5:02, 6:07

    health care in 2014, but not every health-care stock did well, including wide-moat [TICKER: SNY ] Sanofi . Glaser: Health-care stocks looked very strong in 2014, driven partially by an M&A boom. But [TICKER: SNY ] Sanofi looked a lot weaker, and there are a few things happening here. One were fundamental concerns about the business. Questions about what's
    able to actually reap those cash flows. We saw this stewardship hiccup at [TICKER: SNY ] Sanofi , and investors weren't happy about that. I think this highlights the importance of making sure that strong stewardship is there instead of
  9. Health Care: A Strong Run, but Some Stocks Still Look Undervalued

    Headlines

    Wed, 31 Dec 2014

    Wide Medium SEK 65.50 Sanofi $59 Wide Medium $41 ..... positioned for growth. Sanofi SNY Despite some weakness in ..... insulin drugs, we expect Sanofi 's key narrow- and wide ..... community underappreciates Sanofi 's strong competitive advantages

  10. From Barron’s, December 1, 2014 (Part 1)

    Commentary

    Sat, 29 Nov 2014

    Russell 2000 +0.07% . DJ Transports +1.14% , DJ Utilities +0.60 % . Pg M6, Europe: French big pharma Sanofi [ SAN .fr/ SNY ; flat YTD; fwd P/E 14.4; CEO search ongoing], Finnish telecom-network company Nokia [ NOK ; +15% YTD; sold

« Prev12345Next »
Content Partners